TECNOTREE
1.8.2024 15:30:28 CEST | Business Wire | Press release
Tecnotree, a global digital platform and services leader for BSS, OSS, AI, 5G, and cloud-native technologies, has partnered with MiFibra, a leading High-Speed Broadband Internet Service Provider in Perú, to update its Operations Support Systems and transform Fulfillment and Assurance processes.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240801164212/en/
Tecnotree and MiFibra Collaborate to Revolutionize its Operations Support Systems (Graphic: Business Wire)
The strategic partnership will allow MiFibra to fully realize the potential of its Fiber to the Home (FTTH) network infrastructure, offering several benefits, such as the capability to automate feasibility, provisioning and maintenance of services, removing complexities and delays related to manual tasks, as well offering the capability to guarantee the quality of services (QoS) and the quality of the experience (QoE). The results of this partnership will allow MiFibra to accelerate the growth of its customer base, increase customer satisfaction and strengthen its position in the market.
It will also expose TMForum's open APIs for service qualification and activation, enabling seamless integration and compatibility with a variety of protocols and network elements. MiFibra will be able to fully optimize the capacity and usage of its network infrastructure, and, through efficient resources management, it will be able to achieve operational excellence.
Carlos Villegas, CEO of MiFibra, said: "The partnership between MiFibra and Tecnotree represents a transformative step towards comprehensive provisioning with greater and better information for commercial and technical customer management. Through this strategic alliance, MiFibra will be able to evolve its commercial and technical service platforms over time by incorporating digital self-management tools for the customer, a proactive communication portal for the customer, and tools for optimizing home equipment."
Padma Ravichander, CEO of Tecnotree Corporation, said, “We are delighted with this new partnership with MiFibra to embark on a transformative journey towards digitalization and operational efficiency, by revolutionizing their infrastructure and operational support systems. By leveraging our expertise in BSS, OSS, Artificial Intelligence and 5G technologies, Tecnotree will enable MiFibra to unlock its true potential and drive growth by provisioning services quicker and assurance of quality of its services. Through increased automation and streamlined processes, we will enable fast and agile interactions at scale, which will not only fuel MiFibra's customer base, but will also fortify their market position.”
About Tecnotree
Tecnotree is a 5G-ready digital Business Support System (BSS) & Operating Support System (OSS) player, with AI/ML capabilities and multi-cloud extensibility. Tecnotree is No. 1 on the TM Forum Open API Conformance table with 59 Open APIs, a result of our pursuit of delivering excellence, and consistently providing differentiated experiences and services to the CSPs and DSPs. Our agile and open-source Digital BSS Stack comprises the full range (order-to-cash) of business processes and subscription management for telecom and other digital services industries creating opportunities beyond connectivity. Tecnotree also provides Fintech and B2B2X multi-experience digital marketplace to its subscriber base through the Tecnotree Moments platform to empower digitally connected communities across gaming, health, education, OTT, and other vertical ecosystems. Tecnotree is listed on the Helsinki Nasdaq (TEM1V).
About MiFibra
MiFibra is a company founded by Peruvian executives with over 20 years of experience in the telecommunications sector. It currently has broadband fiber optic networks in the departments of Piura, Lambayeque, Trujillo, and Ancash, with coverage of more than 800,000 households and over 80,000 connected customers. It has been recognized by Ookla as the leading Fixed Internet operator in terms of speed in all the departments where it operates. Its mission is to bring world-class internet service to more and more Peruvians, and its vision is to become the number one operator wherever it operates.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240801164212/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Doubtless Pet Care Launches to Provide Peace of Mind to Pet Parents and Help Their Pets Live Happier, Healthier Lives29.6.2026 10:15:00 CEST | Press release
Doubtless combines industry-leading pet insurance with innovative care solutions, protecting more than 6 million pets across 10 global markets Doubtless launches today with the goal of helping more pet parents across the world access quality care for the pets they love. The company brings together a leading global portfolio of pet insurance brands with a growing range of connected solutions designed to support pet parents at every stage of their pet’s life. With over 4,000 employees, Doubtless insures 6 million pets across 10 markets in North America, Europe and the United Kingdom. “Uncertainty about the financial commitments associated with having a pet should never keep families from experiencing the joy of a life with pets,” said Dirk Beeckman, CEO of Doubtless. “By harnessing the power of our international footprint, we are building on our leadership in pet insurance to create a global suite of solutions for pet parents, veterinarians and industry partners that makes pet care easie
Samsung Bioepis Announces Positive Preliminary Phase 1 and Phase 3 Data for SB27, a Proposed Biosimilar to Keytruda (Pembrolizumab)29.6.2026 09:19:00 CEST | Press release
Phase 1 study demonstrated pharmacokinetic (PK) equivalence between SB27 and Keytruda; Phase 3 study demonstrated equivalent objective response rate (ORR) at Week 24Phase 1 and Phase 3 studies expected to be completed within 2026 Samsung Bioepis Co., Ltd. announced today that the Phase 1 and Phase 3 studies on SB27, a proposed biosimilar to Keytruda1 (pembrolizumab), have met their primary endpoints. “We are excited to announce preliminary results from the Phase 1 and Phase 3 studies for SB27, our pembrolizumab biosimilar candidate. These topline positive results reinforce our scientific expertise and leadership in biosimilar development,” said Donghoon Shin, Executive Vice President and Head of Clinical Sciences Division at Samsung Bioepis. “We are on track to complete both Phase 1 and Phase 3 studies within this year. Leveraging our robust quality management system, we remain committed to advancing our biosimilar portfolio to broaden access to life-saving biologic medicines for patie
IQM Named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment29.6.2026 09:00:00 CEST | Press release
IQM today announced it has been named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260629748732/en/ IQM named a major player in the IDC MarketScape IQM believes this recognition comes as institutions worldwide move quantum computing out of shared cloud access and into infrastructure they own and operate themselves. IQM calls this Production Quantum: full-stack, open-architecture superconducting systems deployed on premises, inside customers' own data centers and HPC environments, where organizations own the hardware, build internal expertise, and run quantum processors alongside their existing classical infrastructure. According to the IDC MarketScape, "For institutions building long-term quantum programs, this means the workflows and intellectual property developed on IQM hardware remain portable." The report further advises: "Consi
Zambon Announces Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson’s Disease and Moderate to Severe Motor Fluctuations29.6.2026 09:00:00 CEST | Press release
Positive CHMP opinion is based on data from the Phase 3 RISE-PD trial, which demonstrated significantly more “Good ON” time with fewer daily doses compared with immediate-release levodopa/carbidopa More than one million people are living with Parkinson’s disease in the European Union, and over 80% experience motor fluctuations during the course of their disease, highlighting the need for additional treatment options Hopledo® contains a unique formulation combining immediate-release granules and extended-release pellets, providing both a rapid onset of action and a longer duration of effect, sustaining the levodopa therapeutic effect for a longer period of time If approved, Zambon expects to make Hopledo® progressively available to patients with Parkinson’s disease across Europe starting October 2026 Zambon today announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a marketing authorization by the European M
Enhertu® Approved in the EU as First Tumor Agnostic HER2 Directed Therapy and Antibody Drug Conjugate for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors29.6.2026 08:30:00 CEST | Press release
Approval based on three phase 2 trials of Daiichi Sankyo and AstraZeneca’s Enhertu that demonstrated clinically meaningful responses across a broad range of tumors Enhertu now approved for six indications in the EU Enhertu® (trastuzumab deruxtecan) has been approved in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinion of the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from subgroups of patients with HER2 positive (IHC 3+) tumors across thr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom